[Squamous Cell Carcinoma of the Head and Neck. Photodynamic Therapy with Foscan]

Overview

Journal HNO

Specialty Otorhinolaryngology

Date 2007 May 23

PMID 17516041

Citations 8

Authors

K J Lorenz

H Maier

Affiliations

Soon will be listed here.

Abstract

Introduction: Photodynamic therapy (PDT) is a relatively new method of treating superficial tumours of the skin or mucous membranes. After the injection of a photosensitiser, the tumour area is exposed to non-thermal laser light. This causes a phototoxic reaction, producing oxygen radicals that destroy the tumour cells.

Patients And Methods: From November 2004 to February 2006, a total of 24 patients with recurrent or secondary tumours after squamous cell carcinoma of the head and neck were treated with PDT at the German Armed Forces Hospital in Ulm after other treatment options had failed. Meta-tetrahydroxyphenyl chlorin (mTHPC), known under the trade name of Foscan, was used as the photosensitising agent.

Results: Complete remission was observed in 12 patients (50%) and partial remission was seen in nine (37.5%). Three patients did not respond to treatment. The mean duration of overall survival was 305.7 days (+/-199.4) after completion of treatment. The mean duration of recurrence-free survival was 302.7 days (+/-144.9) for patients with complete remission. There were no serious complications.

Conclusions: Photodynamic therapy is an important treatment option for patients who develop recurrent or secondary tumours after squamous cell carcinoma of the upper aerodigestive tract and fail to respond to other treatments. In addition, PDT may play a role in the primary treatment of superficial tumours of the oral cavity, pharynx and larynx in the future.

Citing Articles

Antitumor Immunity Mediated by Photodynamic Therapy Using Injectable Chitosan Hydrogels for Intratumoral and Sustained Drug Delivery.

Gierlich P, Donohoe C, Behan K, Kelly D, Senge M, Gomes-da-Silva L Biomacromolecules. 2023; 25(1):24-42.

PMID: 37890872 PMC: 10778090. DOI: 10.1021/acs.biomac.3c00591.

Computational identification of repurposed drugs against viruses causing epidemics and pandemics via drug-target network analysis.

Rajput A, Thakur A, Rastogi A, Choudhury S, Kumar M Comput Biol Med. 2021; 136:104677.

PMID: 34332351 PMC: 8299294. DOI: 10.1016/j.compbiomed.2021.104677.

Computation screening and molecular docking of FDA approved viral protease inhibitors as a potential drug against COVID-19.

Absalan A, Doroud D, Salehi-Vaziri M, Kaghazian H, Ahmadi N, Zali F Gastroenterol Hepatol Bed Bench. 2020; 13(4):355-360.

PMID: 33244378 PMC: 7682959.

Plasma-derived Exosomes Reverse Epithelial-to-Mesenchymal Transition after Photodynamic Therapy of Patients with Head and Neck Cancer.

Theodoraki M, Yerneni S, Brunner C, Theodorakis J, Hoffmann T, Whiteside T Oncoscience. 2018; 5(3-4):75-87.

PMID: 29854876 PMC: 5978437. DOI: 10.18632/oncoscience.410.

Determinants for further wishes for cosmetic and reconstructive interventions in 1652 patients with surgical treated carcinomas of the oral cavity.

Holtmann H, Spalthoff S, Gellrich N, Handschel J, Lommen J, Kubler N Maxillofac Plast Reconstr Surg. 2017; 39(1):26.

PMID: 28944220 PMC: 5583133. DOI: 10.1186/s40902-017-0125-1.

References

Biel M . Photodynamic therapy and the treatment of head and neck cancers. J Clin Laser Med Surg. 1996; 14(5):239-44. DOI: 10.1089/clm.1996.14.239. View

Galante E, Gallus G, Chiesa F, Bono A, Bettoni I, Molinari R . Growth rate of head and neck tumors. Eur J Cancer Clin Oncol. 1982; 18(8):707-12. DOI: 10.1016/0277-5379(82)90067-0. View

Foote C, Shook F, Abakerli R . Characterization of singlet oxygen. Methods Enzymol. 1984; 105:36-47. DOI: 10.1016/s0076-6879(84)05006-0. View

Wong S, Machtay M, Li Y . Locally recurrent, previously irradiated head and neck cancer: concurrent re-irradiation and chemotherapy, or chemotherapy alone?. J Clin Oncol. 2006; 24(17):2653-8. DOI: 10.1200/JCO.2005.05.3850. View

Forastiere A, Metch B, Schuller D, Ensley J, Hutchins L, Triozzi P . Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study. J Clin Oncol. 1992; 10(8):1245-51. DOI: 10.1200/JCO.1992.10.8.1245. View

Heimlich F, Dietz A, Daniel V, Maier H . [Immunosuppression caused by head and neck surgery]. HNO. 1999; 47(10):885-92. DOI: 10.1007/s001060050529. View

Maier H, Daniel V, Heimlich F, Frank C, Opelz G . [Cellular immune defect caused by postoperative irradiation in patients with squamous epithelial carcinomas of the upper aerodigestive tract]. HNO. 1995; 43(6):364-70. View

Kramer S, MARCIAL V, Pajak T, MacLean C, Davis L . Prognostic factors for loco/regional control and metastasis and the impact on survival. Int J Radiat Oncol Biol Phys. 1986; 12(4):573-8. DOI: 10.1016/0360-3016(86)90065-9. View

Copper M, Tan I, Oppelaar H, Ruevekamp M, Stewart F . Meta-tetra(hydroxyphenyl)chlorin photodynamic therapy in early-stage squamous cell carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg. 2003; 129(7):709-11. DOI: 10.1001/archotol.129.7.709. View

10.

Weymuller Jr E, Alsarraf R, Yueh B, Deleyiannis F, Coltrera M . Analysis of the performance characteristics of the University of Washington Quality of Life instrument and its modification (UW-QOL-R). Arch Otolaryngol Head Neck Surg. 2001; 127(5):489-93. DOI: 10.1001/archotol.127.5.489. View

11.

Moosmann P, Egli F, Stahel R, Jost L . Weekly paclitaxel and carboplatin combination chemotherapy in patients with advanced squamous cell carcinoma of the head and neck. Onkologie. 2004; 26(6):568-72. DOI: 10.1159/000074153. View

12.

Betz C, Leunig A . . HNO. 2017; 52(2):175-192. DOI: 10.1007/s00106-003-1029-1. View

13.

DCruz A, Robinson M, Biel M . mTHPC-mediated photodynamic therapy in patients with advanced, incurable head and neck cancer: a multicenter study of 128 patients. Head Neck. 2004; 26(3):232-40. DOI: 10.1002/hed.10372. View

14.

Forastiere A, Koch W, Trotti A, Sidransky D . Head and neck cancer. N Engl J Med. 2002; 345(26):1890-900. DOI: 10.1056/NEJMra001375. View

15.

Gedlicka C, Formanek M, Selzer E, Burian M, Kornfehl J, Fiebiger W . Phase II study with docetaxel and cisplatin in the treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck. Oncology. 2002; 63(2):145-50. DOI: 10.1159/000063809. View

16.

Foote C . Mechanisms of photooxygenation. Prog Clin Biol Res. 1984; 170:3-18. View

17.

Munro A, Sebag-Montefiore D . Opportunity cost--a neglected aspect of cancer treatment. Br J Cancer. 1992; 65(3):309-10. PMC: 1977601. DOI: 10.1038/bjc.1992.64. View

18.

Grant W, Hopper C, Speight P, MacRobert A, Bown S . Photodynamic therapy of malignant and premalignant lesions in patients with 'field cancerization' of the oral cavity. J Laryngol Otol. 1993; 107(12):1140-5. DOI: 10.1017/s0022215100125496. View

19.

Hopper C, Kubler A, Lewis H, Tan I, Putnam G . mTHPC-mediated photodynamic therapy for early oral squamous cell carcinoma. Int J Cancer. 2004; 111(1):138-46. DOI: 10.1002/ijc.20209. View

20.

Nollert J, Rudat V, Daniel V, Maier H, Dietz A . [Effect of primary radiochemotherapy on cellular and subcellular immunologic parameters]. HNO. 2000; 47(12):1058-62. DOI: 10.1007/s001060050491. View